Copy Link Print Information

Nedisertib

(Synonyms: Peposertib; M3814)
31 Cited Publications
Kundenbewertung

Based on 31 publication(s) in Google Scholar

Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.70%
  • CAS. Nr.: 1637542-33-6
  • Formel: C24H21ClFN5O3
  • Molecular Weight:481.91
  • Speicherung:

    -20°C, protect from light, stored under nitrogen

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

  • Nedisertib Chemical Structure
    Nedisertib Chemical Structure
  • Experimental Validation Results for Nedisertib
  • Experimental Validation Results for Nedisertib
  • Experimental Validation Results for Nedisertib
  • Experimental Validation Results for Nedisertib
  • Experimental Validation Results for Nedisertib
CAS. Nr.: 1637542-33-6
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Nedisertib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Nedisertib

More
Customer Validation & Images
Bio/Physico-chemical AssayCell Proliferation/Viability AssayFlow CytometryIF
  • Bio/Physico-chemical Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • IF
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Nedisertib Chemical Structure
    Nedisertib Chemical Structure
    1/16
  • 1/16

    Nedisertib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Jun 27;13(1):3662. [Abstract]

    Customer Validation
     Effect of DNAPKcs kinase inhibitor M3814 (3 days) on No Indel EJ in HEK293 cells with XLF-WT, XLF-K160D, and without XLF was examined.

  • 1/16

    Nedisertib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Dec;11(12):3935-3949. [Abstract]

    Customer Validation
     Cell viability curves of NSCLC cell lines A549 treated with paclitaxel (PTX) and etoposide (Etop), in the absence or presence of M3814 (5 mmol/L) for 48 h were analyzed.

  • 1/16

    Nedisertib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Dec;11(12):3935-3949. [Abstract]

    Customer Validation
     Quantitative data of the EdU-positive fraction. Representative images of colonies from colony formation assays in A549, H460, and H1703 cells treated with paclitaxel (5 nmol/L) and etoposide (100 nmol/L) in the absence or presence of M3814 (5 μmol/L) for 18 h, followed by incubation in 6-well plates for another 14 days.

  • 1/16

    Nedisertib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Dec;11(12):3935-3949. [Abstract]

    Customer Validation
     NSCLC cell lines A549, H460, and H1703 were treated with paclitaxel (5 nmol/L) and etoposide (100 nmol/L) with or without M3814 (5 mmol/L) for 48 h, stained with Annexin V/PI, and evaluated through flow cytometry.

  • 1/16

    Nedisertib purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Dec;11(12):3935-3949. [Abstract]

    Customer Validation
     Representative images of NSCLC cells incubated in the presence or absence of 5 mmol/L M3814 for 1 h before adding 100 nmol/L paclitaxel or 1 mmol/L etoposide. Following extensive washing in drug-free medium, cells were incubated with or without 5 mmol/L M3814 for another 4 h, and immunostained for γ-H2AX (red) foci. DAPI staining (blue fluorescence), scale bar = 10 μm (magnification, 1000×).

  • Nedisertib